[go: up one dir, main page]

AR127635A1 - ANTICUERPO MONOCLONAL O FRAGMENTO DE UNIÓN A UN ANTÍGENO QUE SE UNE ESPECÍFICAMENTE A LA IL-4Ra, Y USO DEL MISMO - Google Patents

ANTICUERPO MONOCLONAL O FRAGMENTO DE UNIÓN A UN ANTÍGENO QUE SE UNE ESPECÍFICAMENTE A LA IL-4Ra, Y USO DEL MISMO

Info

Publication number
AR127635A1
AR127635A1 ARP220103093A ARP220103093A AR127635A1 AR 127635 A1 AR127635 A1 AR 127635A1 AR P220103093 A ARP220103093 A AR P220103093A AR P220103093 A ARP220103093 A AR P220103093A AR 127635 A1 AR127635 A1 AR 127635A1
Authority
AR
Argentina
Prior art keywords
antigen
binding fragment
specifically binds
monoclonal antibody
disorders
Prior art date
Application number
ARP220103093A
Other languages
English (en)
Inventor
Alina Valerevna Beliasnikova
Olga Leonidovna Kytmanova
Darya Olegovna Chernyshova
Mariia Aleksandrovna Shchemeleva
Anastasilia Isaevna Afremova
Dmitry Valentinovich Morozov
Original Assignee
Joint Stock Company “Biocad”
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from RU2021132869A external-priority patent/RU2808563C2/ru
Application filed by Joint Stock Company “Biocad” filed Critical Joint Stock Company “Biocad”
Publication of AR127635A1 publication Critical patent/AR127635A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5406—IL-4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención se refiere al campo de la biotecnología y la medicina, en particular a un anticuerpo monoclonal o fragmento de unión a antígeno del mismo que se une específicamente a la IL-4Ra (subunidad a del receptor de interleucina-4). La invención se refiere además a ácidos nucleicos que codifican dicho anticuerpo, vectores de expresión, células huésped y métodos para producirlos, métodos para producir los anticuerpos según la invención, composiciones farmacéuticas que comprenden el anticuerpo según la invención, composiciones farmacéuticas que comprenden el anticuerpo según la invención y otros compuestos terapéuticamente activos, métodos para tratar enfermedades o trastornos mediados por IL-4Ra, usos de los anticuerpos o composiciones farmacéuticas de los mismos para tratar enfermedades o trastornos mediados por IL-4Ra, y usos de los anticuerpos y otros compuestos terapéuticamente activos para tratar enfermedades o trastornos mediados por IL-4Ra.
ARP220103093A 2021-11-11 2022-11-10 ANTICUERPO MONOCLONAL O FRAGMENTO DE UNIÓN A UN ANTÍGENO QUE SE UNE ESPECÍFICAMENTE A LA IL-4Ra, Y USO DEL MISMO AR127635A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2021132869A RU2808563C2 (ru) 2021-11-11 МОНОКЛОНАЛЬНОЕ АНТИТЕЛО ИЛИ ЕГО АНТИГЕНСВЯЗЫВАЮЩИЙ ФРАГМЕНТ, КОТОРОЕ СПЕЦИФИЧЕСКИ СВЯЗЫВАЕТСЯ С IL-4Rα, И ЕГО ПРИМЕНЕНИЕ

Publications (1)

Publication Number Publication Date
AR127635A1 true AR127635A1 (es) 2024-02-14

Family

ID=86336553

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP220103093A AR127635A1 (es) 2021-11-11 2022-11-10 ANTICUERPO MONOCLONAL O FRAGMENTO DE UNIÓN A UN ANTÍGENO QUE SE UNE ESPECÍFICAMENTE A LA IL-4Ra, Y USO DEL MISMO

Country Status (3)

Country Link
AR (1) AR127635A1 (es)
UY (1) UY40013A (es)
WO (1) WO2023085978A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR134102A1 (es) * 2023-10-12 2025-12-03 Innovent Biologics Suzhou Co Ltd ANTICUERPOS ANTI-IL-4Ra Y USOS DE LOS MISMOS

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001272925A1 (en) * 2000-05-26 2001-12-11 Immunex Corporation Use of interleukin-4 antagonists and compositions thereof
EP1692184B1 (en) * 2003-11-07 2012-03-07 Immunex Corporation Antibodies that bind interleukin-4 receptor
US7608693B2 (en) * 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
KR102652133B1 (ko) * 2018-02-01 2024-03-29 베이징 카윈 테크놀로지 쉐어-홀딩 컴퍼니 리미티드 IL-4Rα 항체 및 그 용도

Also Published As

Publication number Publication date
UY40013A (es) 2023-05-31
WO2023085978A1 (en) 2023-05-19

Similar Documents

Publication Publication Date Title
CL2020000452A1 (es) Anticuerpos de b7-h4 y métodos para usarlos.
PE20211284A1 (es) Anticuerpos anti-nkg2a y usos de los mismos
RU2018139811A (ru) Мультиспецифические антигенсвязывающие конструкции, нацеливающие иммунотерапевтические средства
MX2020003888A (es) Anticuerpos terapeuticos postraduccionalmente modificados completamente humanos.
PE20221580A1 (es) Anticuerpos terapeuticos y sus usos
AR053608A1 (es) Anticuerpos anti-gm-csf y usos de los mismos
PE20211792A1 (es) Anticuerpos monoclonales que se unen especificamene a la region beta de la familia trbv-9 del receptor de celulas t humano, y los metodos para su uso
CO2021009689A2 (es) Anticuerpos monoclonales que se unen específicamente a la región beta de la familia trbv-9 del receptor de células t humano, y los métodos para su uso.
PE20230464A1 (es) Union de anticuerpos multiespecificos a bcma
EA202092125A1 (ru) Антитела против рецептора фолата 1 и их применения
MX2021012488A (es) Receptores de antigeno quimerico del receptor 1 anti-folato humanizado y usos de los mismos.
EA202192907A1 (ru) Моноклональное антитело, которое специфически связывается с gitr
CO2024010847A2 (es) Construcciones de vectores para la distribución de ácidos nucleicos que codifican anticuerpos terapéuticos anti-igf-1r y métodos para usarlos
AR127635A1 (es) ANTICUERPO MONOCLONAL O FRAGMENTO DE UNIÓN A UN ANTÍGENO QUE SE UNE ESPECÍFICAMENTE A LA IL-4Ra, Y USO DEL MISMO
MX2025008324A (es) Anticuerpos multiespecificos y usos de estos
CO2025009946A2 (es) Proteínas de unión al antígeno anti-tnfr2 y sus usos
CO2023012549A2 (es) Anticuerpo monoclonal o fragmento de unión al antígeno del mismo que se une específicamente al gd2 (gangliósido gd2), y uso del mismo
AR129553A1 (es) Anticuerpo monoclonal o fragmento de unión al antígeno del mismo que se une específicamente a bcma, y uso del mismo
AR132867A1 (es) Anticuerpo monoclonal o fragmento de unión a antígeno del mismo que se une específicamente a axl, y uso del mismo
MX2022004058A (es) Kir3dl3 es un receptor inhibidor del sistema inmunitario y usos del mismo.
AR132099A1 (es) Anticuerpo biespecífico aislado que se une específicamente al cd3 y al antígeno tumoral, y uso del mismo
CL2023003854A1 (es) Anticuerpo biespecífico aislado que se une específicamente a cd47 y pd-l1
CL2018002690A1 (es) Variantes del anticuerpo humanizado ban2401 que se une específicamente a protofibrillas con una vida media serica aumentada composiciones farmacéuticas y usos en el tratamiento del alzheimer y otras enfermedades neurodegenerativas (divisional de la solicitud n° 53-2017).
CO2024008181A2 (es) Anticuerpos b7-h4 y anticuerpo anti-b7-h4/ proteínas de fusión il-15
AR132063A1 (es) Anticuerpos multiespecíficos anti-cldn6 y anti-cd3 y métodos de uso